Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets.

Yadav V, Varum F, Bravo R, Furrer E, Bojic D, Basit AW.

Transl Res. 2016 Oct;176:38-68. doi: 10.1016/j.trsl.2016.04.009. Epub 2016 May 6. Review.

PMID:
27220087
2.

Gastrointestinal stability of therapeutic anti-TNF α IgG1 monoclonal antibodies.

Yadav V, Varum F, Bravo R, Furrer E, Basit AW.

Int J Pharm. 2016 Apr 11;502(1-2):181-7. doi: 10.1016/j.ijpharm.2016.02.014. Epub 2016 Feb 15.

PMID:
26892815
3.

Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.

Chandrasekharan S, Amin T, Kim J, Furrer E, Matterson AC, Schwalbe N, Nguyen A.

Vaccine. 2015 Nov 17;33(46):6366-70. doi: 10.1016/j.vaccine.2015.08.063. Epub 2015 Sep 11.

4.

Prediction of immunisation performance.

Hanson CM, Furrer E, Schwalbe N, Berkley S.

Lancet. 2013 Feb 2;381(9864):349-50. doi: 10.1016/S0140-6736(12)62165-5. No abstract available.

PMID:
23374462
5.

Predictive ability of the ISS, NISS, and APACHE II score for SIRS and sepsis in polytrauma patients.

Mica L, Furrer E, Keel M, Trentz O.

Eur J Trauma Emerg Surg. 2012 Dec;38(6):665-71. doi: 10.1007/s00068-012-0227-5. Epub 2012 Sep 18.

PMID:
26814554
6.

Advance market commitment for pneumococcal vaccines: putting theory into practice.

Cernuschi T, Furrer E, Schwalbe N, Jones A, Berndt ER, McAdams S.

Bull World Health Organ. 2011 Dec 1;89(12):913-8. doi: 10.2471/BLT.11.087700. Epub 2011 Oct 7.

7.

NrdH-redoxin protein mediates high enzyme activity in manganese-reconstituted ribonucleotide reductase from Bacillus anthracis.

Crona M, Torrents E, Røhr AK, Hofer A, Furrer E, Tomter AB, Andersson KK, Sahlin M, Sjöberg BM.

J Biol Chem. 2011 Sep 23;286(38):33053-60. doi: 10.1074/jbc.M111.278119. Epub 2011 Aug 6.

8.

Subunit and small-molecule interaction of ribonucleotide reductases via surface plasmon resonance biosensor analyses.

Crona M, Furrer E, Torrents E, Edgell DR, Sjöberg BM.

Protein Eng Des Sel. 2010 Aug;23(8):633-41. doi: 10.1093/protein/gzq035. Epub 2010 Jun 9.

9.

Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain.

Furrer E, Hulmann V, Urech DM.

J Neuroimmunol. 2009 Oct 30;215(1-2):65-72. doi: 10.1016/j.jneuroim.2009.08.005. Epub 2009 Sep 5.

PMID:
19733918
10.
11.

Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.

Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U, Lichtlen P, Urech DM.

Invest Ophthalmol Vis Sci. 2009 Feb;50(2):771-8. doi: 10.1167/iovs.08-2370. Epub 2008 Aug 29.

PMID:
18757508
12.

Functional characterization of a NapA Na(+)/H(+) antiporter from Thermus thermophilus.

Furrer EM, Ronchetti MF, Verrey F, Pos KM.

FEBS Lett. 2007 Feb 6;581(3):572-8. Epub 2007 Jan 17.

13.

Neutral amino acid transport mediated by ortholog of imino acid transporter SIT1/SLC6A20 in opossum kidney cells.

Ristic Z, Camargo SM, Romeo E, Bodoy S, Bertran J, Palacin M, Makrides V, Furrer EM, Verrey F.

Am J Physiol Renal Physiol. 2006 Apr;290(4):F880-7. Epub 2005 Oct 18.

14.

Water-in-water mesophases for templating inorganics.

Taubert A, Furrer E, Meier W.

Chem Commun (Camb). 2004 Oct 7;(19):2170-1. Epub 2004 Sep 2.

PMID:
15467856
15.
18.

A functional role for neutralizing antibodies in Borna disease: influence on virus tropism outside the central nervous system.

Stitz L, Nöske K, Planz O, Furrer E, Lipkin WI, Bilzer T.

J Virol. 1998 Nov;72(11):8884-92.

Supplemental Content

Loading ...
Support Center